PARP1 and neoplasm: Overall, our studies demonstrate that oncogenic activation of RAS/MAPK signaling is a key feature of MPM, independent of tumor heterogeneity, and that MAPK signaling and PARP1 homeostatically regulate ROS and promote evasion of ROS-mediated apoptosis, providing a novel therapeutic rationale for the treatment of the disease.